Concepedia

Author

Chiara Pircher

Istituti di Ricovero e Cura a Carattere ScientificoORCID

Also Known As

C Pircher, C. Pircher, C.C. Pircher, Chiara C. Pircher, Chiara Carlotta Pircher, Chiara Pircher, Hong Jae Chon, Katia Dotti

70

Publications

801

Citations

12

H-Index

9

Concepts

All Affiliations

Istituti di Ricovero e Cura a Carattere ScientificoFondazione IRCCS Istituto Nazionale dei TumoriIstituto Oncologico VenetoVita-Salute San Raffaele UniversityAzienda Ospedaliera Universitaria Pisana
CP

About

Chiara Pircher is an author at Istituti di Ricovero e Cura a Carattere Scientifico specializing in oncology, radiation oncology, and cancer therapeutics.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

3

3

372

2

Cancer Therapeutics

3

3

372

3

Pharmacology

2

2

123

4

Surgical Oncology

2

2

306

5

Pathology

1

1

57

Chiara Pircher

×

10

Publications

526

Citations

10

H-Index

YearCitations

Safety and efficacy of preoperative or postoperative chemotherapy for resectable pancreatic adenocarcinoma (PACT-15): a randomised, open-label, phase 2–3 trial

Michele Reni, Gianpaolo Balzano, Silvia Zanon,

˜The œLancet. Gastroenterology & hepatology

2018

249

Nab-paclitaxel plus gemcitabine with or without capecitabine and cisplatin in metastatic pancreatic adenocarcinoma (PACT-19): a randomised phase 2 trial

Michele Reni, Silvia Zanon, Umberto Peretti,

˜The œLancet. Gastroenterology & hepatology

2018

66

A randomised phase 2 trial of nab-paclitaxel plus gemcitabine with or without capecitabine and cisplatin in locally advanced or borderline resectable pancreatic adenocarcinoma

Michele Reni, Silvia Zanon, Gianpaolo Balzano,

European Journal of Cancer

2018

57

A multicenter phase 2 single arm study of cabozantinib in patients with advanced or unresectable renal cell carcinoma pre-treated with one immune-checkpoint inhibitor: The BREAKPOINT trial (Meet-Uro trial 03)

Giuseppe Procopio, Mélanie Claps, Chiara Pircher,

Tumori Journal

2022

46

Real-world data to build explainable trustworthy artificial intelligence models for prediction of immunotherapy efficacy in NSCLC patients

Arsela Prelaj, Edoardo Gregorio Galli, V. Miskovic,

Frontiers in Oncology

2023

30

Negative Ultraselection of Patients With <i>RAS</i>/<i>BRAF</i> Wild-Type, Microsatellite-Stable Metastatic Colorectal Cancer Receiving Anti–EGFR-Based Therapy

Giovanni Randon, Giulia Maddalena, Marco Maria Germani,

JCO Precision Oncology

2022

28

Ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line oxaliplatin-based chemotherapy in patients with advanced HER2-negative gastric or gastro-oesophageal junction cancer (ARMANI): a randomised, open-label, multicentre, phase 3 trial

Giovanni Randon, Sara Lonardi, Matteo Fassan,

The Lancet Oncology

2024

17

A phase II/III randomized clinical trial of CisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative chemotherapy versus immediate resection in patIents with resecTable BiliarY Tract Cancers (BTC) at high risk for recurrence: PURITY study

Monica Niger, Federico Nichetti, Lorenzo Fornaro,

BMC Cancer

2024

13

Platinum sensitivity in patients with <i>IDH1/2</i> mutated vs wild‐type intrahepatic cholangiocarcinoma: A propensity score‐based study

Monica Niger, Federico Nichetti, Andrea Casadei‐Gardini,

International Journal of Cancer

2022

10

Different Genomic Clusters Impact on Responses in Advanced Biliary Tract Cancer Treated with Cisplatin Plus Gemcitabine Plus Durvalumab

Margherita Rimini, Eleonora Loi, Mario Domenico Rizzato,

Targeted Oncology

2024

10

Page 1